已收盤 02-06 16:00:00 美东时间
+0.010
+0.02%
INDIANA, Pa., Jan. 28, 2026 /PRNewswire/ -- The board of directors of S&T Bancorp, Inc. (S&T) (NASDAQ: STBA), the holding company for S&T Bank, approved a $0.36 per share cash dividend on Ja...
01-29 05:35
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据S&T Bancorp业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **第四季度业绩表现:** - 净收入:3400万美元,每股收益0.89美元 - 资产回报率(ROA):1.37% - 净息差(NIM):3.99%,环比上升6个基点,为2023年以来最高水平 - 净息收入:环比增长180万美元,增幅接近2% **全年2025年业绩:** - 全年净收入:接近1.35亿美元 - 全年每股收益:3.49美元 - 全年净息差:3.9% - 净冲销率:全年18个基点 ## 2. 财务指标变化 **资产负债表变化:** - 贷款增长:第四季
01-23 12:15
S&T Bancorp (NASDAQ:STBA) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.88 by 1.71 percent. This is a 3.49 percent increase over earnings of $0.86 per share from the same
01-22 20:32
S&T Bancorp, Inc. (S&T) (NASDAQ:STBA), the holding company for S&T Bank, announced that the board of directors authorized a new $100 million share repurchase program at its meeting held January 21, 2026. The
01-22 20:23
INDIANA, Pa., Jan. 22, 2026 /PRNewswire/ -- S&T Bancorp, Inc. (S&T) (NASDAQ: STBA), the holding company for S&T Bank, announced that the board of directors authorized a new $100 million shar...
01-22 20:20
Companies Reporting Before The Bell • Commerce Bancshares (NASDAQ:CBSH) is proj...
01-22 19:11
INDIANA, Pa., Oct. 30, 2025 /PRNewswire/ -- S&T Bancorp, Inc. (S&T) (NASDAQ: STBA), the holding company for S&T Bank, announced today that Stephanie N. Doliveira will join its board of direc...
2025-10-30 22:07
INDIANA, Pa., Oct. 29, 2025 /PRNewswire/ -- The Board of Directors of S&T Bancorp, Inc. (S&T) (NASDAQ: STBA), the holding company for S&T Bank, approved a $0.36 per share cash dividend on Oc...
2025-10-30 05:43
今日重点评级关注:Guggenheim:上调Neumora Therapeutics评级至"买入",目标价14美元;韦德布什:上调Fate Therapeutics评级至"跑赢大市",目标价从5美元升至7美元
2025-10-28 10:08